Agenus (NASDAQ:AGEN – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at Chardan Capital in a research note issued on Thursday, Benzinga reports.
A number of other research analysts have also weighed in on the company. B. Riley Financial reaffirmed a “buy” rating and set a $14.00 target price (up from $8.00) on shares of Agenus in a report on Thursday, July 30th. Wall Street Zen lowered shares of Agenus from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 17th. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target (down from $30.00) on shares of Agenus in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of Agenus from a “sell (d)” rating to a “sell (d+)” rating in a research report on Thursday, October 8th. Finally, Rodman & Renshaw began coverage on shares of Agenus in a research note on Monday, September 28th. They issued a “buy” rating and a $19.00 target price on the stock. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $24.50.
Read Our Latest Research Report on Agenus
Agenus Stock Down 2.8%
AGEN traded down $0.18 during trading on Thursday, hitting $6.33. 509,036 shares of the company traded hands, compared to its average volume of 1,870,427. The firm has a market cap of $285.86 million, a P/E ratio of 2.45 and a beta of 1.31. The stock’s fifty day moving average is $7.70 and its 200 day moving average is $5.50. Agenus has a one year low of $2.71 and a one year high of $10.31.
Agenus (NASDAQ:AGEN – Get Free Report) last released its earnings results on Friday, August 7th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.05 by ($0.06). The firm had revenue of $34.52 million during the quarter, compared to analysts’ expectations of $34.00 million. Agenus had a negative return on equity of 47.68% and a net margin of 69.33%. On average, equities research analysts forecast that Agenus will post -0.30 EPS for the current fiscal year.
Institutional Investors Weigh In On Agenus
Several institutional investors have recently added to or reduced their stakes in the company. Globeflex Capital L P purchased a new position in shares of Agenus during the second quarter valued at about $1,281,000. Bank of America Corp DE grew its holdings in Agenus by 796.7% in the first quarter. Bank of America Corp DE now owns 118,782 shares of the biotechnology company’s stock worth $397,000 after purchasing an additional 105,536 shares during the period. Bank of New York Mellon Corp purchased a new stake in Agenus in the second quarter worth about $311,000. Finally, Everhart Financial Group Inc. bought a new position in shares of Agenus during the third quarter valued at approximately $100,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.
About Agenus
Agenus Inc is a biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research programs are designed to activate and strengthen the immune system’s ability to recognize and attack tumors, with a focus on therapies that may be used across multiple cancer types.
Agenus develops a range of therapeutic approaches, including immune checkpoint inhibitors, cancer vaccines, bispecific antibodies and other antibody-based treatments. Its pipeline has included investigational therapies targeting immune-regulating pathways, as well as combination regimens intended to improve treatment responses and address resistance to existing cancer therapies.
The company was founded in 1994 as Antigenics and adopted the Agenus name in 2011.
Featured Articles
- Five stocks we like better than Agenus
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for Agenus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus and related companies with MarketBeat.com's FREE daily email newsletter.
